The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted robust public health investigations to characterize the disease course. Early published reports identified fever, cough, and shortness of breath as predominant symptoms of COVID-19 \[[@CIT0001], [@CIT0002]\], and these classic symptoms have been used for case identification and testing prioritization. As subsequent reports described a broader range of symptoms, the Council for State and Territorial Epidemiologists (CSTE) updated its list of symptoms compatible with SARS-CoV-2 infection in March 2020 \[[@CIT0003]\], adding loss of taste and smell. Although several reports have described these newly recognized symptoms of loss of taste and smell among individuals diagnosed with COVID-19 \[[@CIT0004]\], few studies have prospectively evaluated these symptoms among close contacts of COVID-19 cases prior to diagnosis and outside of a clinical setting.

The Centers for Disease Control and Prevention (CDC), in partnership with the Wisconsin Department of Health Services and local health departments, conducted a household study that included known COVID-19 index cases and their household members. This investigation provided an opportunity to identify household COVID-19 cases and describe their symptom profiles, including loss of taste and smell, prior to diagnosis.

METHODS {#s1}
=======

All activities in this investigation were part of the public health response and were determined not to be human subjects research. During March--April 2020, health department personnel in Milwaukee County, Wisconsin, assisted the CDC in identifying a convenience sample of households with a laboratory-confirmed COVID-19 index case ≤10 days from diagnosis who resided in the home at enrollment and lived with at least 1 other household member. Informed consent was obtained for all participants. All participants completed questionnaires assessing basic demographic information, medical history, symptoms since the index case's disease onset, and other epidemiological information. A parent or legal guardian assisted in completing questionnaires for children \<18 years of age. At enrollment, we collected nasopharyngeal swabs from all participants; to fulfill a secondary objective of this investigation, we also collected nasal self-collect (NSC) swabs from index cases and symptomatic household members.

The City of Milwaukee Health Department Laboratory tested swabs using the CDC SARS-CoV-2 real-time reverse-transcription polymerase chain reaction assay \[[@CIT0007]\]. We classified any participant having a SARS-CoV-2--positive nasopharyngeal swab or NSC swab collected in the 10 days prior to and including enrollment as a COVID-19 case.

We compared the prevalence of symptoms among cases descriptively and computed bivariate analyses of demographics, medical history, and symptoms with reported loss of taste and/or smell using 2-tailed Pearson χ ^2^ test or Fisher exact test. We calculated the positive predictive value (PPV) and 95% confidence interval (CI) of individual symptoms for COVID-19 among household contacts. Statistical analyses were performed using SAS version 9.4 software (SAS Institute, Cary, North Carolina).

RESULTS {#s2}
=======

We enrolled 90 participants from 26 households, including 26 index cases and 64 household members. Overall, 48 (53%) study participants were male; 69 (77%) were adults ≥18 years of age (median, 31 years \[range, \<1--90 years\]); 41 (46%) were black non-Hispanic/Latino, 37 (41%) were white non-Hispanic/Latino, and 12 (13%) were other races/ethnicities. Preexisting medical conditions were reported by 39 (43%) participants, including asthma or reactive airway disease (n = 13), hypertension (n = 10), and diabetes (n = 8). Upon enrollment, 16 of 64 (25%) household contacts tested positive for SARS-CoV-2 (including 2 who were positive by NSC only), totaling 42 of 90 (47%) COVID-19 cases. The median age of household contacts who tested positive was 21 years (interquartile range \[IQR\], 16--50 years), compared to 23 years (IQR, 12--48 years) for household contacts who tested negative. Median time from symptom onset to enrollment for index cases and symptomatic household cases was 14.5 days (IQR, 10.0--19.0 days) and 7.0 days (IQR, 5.0--7.5 days), respectively.

Among the 42 individuals with laboratory-confirmed SARS-CoV-2, all (100%) reported at least 1 symptom ([Table 1](#T1){ref-type="table"}); 38 (90%) reported at least 1 classic COVID-19 symptom. The most frequently reported symptoms were cough (81%), headache (76%), fever (subjective or measured ≥38.0°C \[≥100.4°F\]) (64%), loss of taste and/or smell (62%), and nasal congestion (62%).

###### 

Prevalence of Self-reported Symptoms Among Individuals With and Without Laboratory-confirmed Coronavirus Disease 2019 (COVID-19), and Positive Predictive Value of Self-reported Symptoms Prior to Testing Among Household Contacts of COVID-19 Index Cases---Milwaukee County, Wisconsin, March--April 2020

  Symptom                               All Cases (N = 42)   Household Index Cases (n = 26)   Household Contact Cases (n = 16)   Household Contact Noncases (n = 48)   Symptom PPV Among Household Contacts (n = 64), % (95% CI)
  ------------------------------------- -------------------- -------------------------------- ---------------------------------- ------------------------------------- -----------------------------------------------------------
  Classic COVID-19 symptoms (any)       38 (90)              24 (92)                          14 (88)                            14 (29)                               50 (33--67)
   Cough                                34 (81)              22 (85)                          12 (75)                            13 (27)                               48 (30--67)
   Fever (any)                          27 (64)              18 (69)                          9 (56)                             3 (6)                                 75 (47--91)
    Measured fever ≥38.0°C (≥100.4°F)   14 (33)              11 (42)                          3 (19)                             1 (2)                                 75 (30--95)
    Subjective fever                    26 (62)              18 (69)                          8 (50)                             2 (4)                                 80 (49--94)
   Shortness of breath                  19 (45)              14 (54)                          5 (31)                             1 (2)                                 83 (44--97)
  Other symptoms (any)                  41 (98)              25 (96)                          16 (100)                           29 (60)                               36 (23--50)
   Headache                             32 (76)              18 (69)                          14 (88)                            16 (33)                               47 (30--64)
   Loss of taste or smell (any)         26 (62)              16 (62)                          10 (63)                            2 (4)                                 83 (55--95)
    Loss of taste (any)                 24 (57)              16 (62)                          8 (50)                             2 (4)                                 80 (49--94)
    Loss of smell (any)                 18 (43)              10 (38)                          8 (50)                             1 (2)                                 89 (57--98)
    Complete loss of taste or smell     16 (38)              10 (38)                          6 (38)                             1 (2)                                 86 (49--97)
     Complete loss of taste             14 (33)              9 (35)                           5 (31)                             1 (2)                                 83 (44--97)
     Complete loss of smell             13 (31)              7 (27)                           6 (38)                             1 (2)                                 86 (49--97)
   Nasal congestion                     26 (62)              14 (54)                          12 (75)                            9 (19)                                57 (37--76)
   Myalgia                              24 (57)              16 (62)                          8 (50)                             3 (6)                                 73 (43--90)
   Chills                               23 (55)              18 (69)                          5 (31)                             3 (6)                                 63 (31--86)
   Rhinorrhea                           20 (48)              12 (46)                          8 (50)                             13 (27)                               38 (21--59)
   Sore throat                          18 (43)              11 (42)                          7 (44)                             10 (21)                               41 (22--64)
   Fatigue^a^                           15 (36)              10 (38)                          5 (31)                             6 (13)                                NR^b^
   Nausea/vomiting                      12 (29)              10 (38)                          2 (13)                             1 (2)                                 67 (21--94)
   Diarrhea                             11 (26)              8 (31)                           3 (19)                             10 (21)                               23 (8--50)
   Abdominal pain                       10 (24)              6 (23)                           4 (25)                             4 (8)                                 50 (22--78)
   Chest pain/discomfort^a^             8 (19)               4 (15)                           4 (25)                             2 (4)                                 NR^b^
   Lightheadedness^a^                   3 (7)                2 (8)                            1 (6)                              0 (0)                                 NR^b^
   Loss of appetite^a^                  3 (7)                3 (12)                           0 (0)                              2 (4)                                 NR^b^
   Wheezing^a^                          3 (7)                2 (8)                            1 (6)                              0 (0)                                 NR^b^
   Other^a,c^                           5 (12)               5 (19)                           0 (0)                              NR^d^                                 NR^b^

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; NR, not reported; PPV, positive predictive value.

^a^Not included in list of symptoms, but self-reported in "other" category.

^b^PPV not reported because symptom was reported in the "other" category and was not systematically evaluated among all participants.

^c^Includes single reports each of difficulty focusing, dry eyes, eye pain, hives, nasal pain, and photosensitivity.

^d^Values not reported for single reports of other symptoms among those who tested SARS-CoV-2 negative (ie, noncases).

Among the 26 participants with COVID-19 who reported loss of taste and/or smell, 24 reported loss of taste with 14 of 24 (58%) reporting complete loss, and 18 participants reported loss of smell with 13 of 18 (72%) reporting complete loss. There were no significant differences in reporting loss of taste and/or smell by sex, age \<18 years vs ≥18 years, race/ethnicity, presence of medical conditions, or between index and household member cases (all *P* \> .05). Of the 26 participants reporting any loss of taste and/or smell, 9 (35%) reported it in the absence of nasal congestion. Participants with COVID-19 reporting loss of taste and/or smell were more likely to report headache (88% vs 56%; *P* = .03), but were no more or less likely to report any other symptom (*P* \> .05). No participant reported loss of taste and/or smell as the only symptom. When loss of taste and/or smell was added to the classic symptoms, 95% of participants with COVID-19 reported at least 1 of loss of taste and/or smell, fever, cough, and shortness of breath.

Among the 64 household members of COVID-19 index cases, loss of taste and/or smell was reported by 12 individuals, 10 of whom were positive for SARS-CoV-2. The PPV of any loss of taste and/or smell (83% \[95% CI, 55%--95%\]) was higher than for fever (subjective or measured) and cough, 2 of the 3 classic symptoms, and equal to the third, shortness of breath (83% \[95% CI, 44%--97%\]) ([Table 1](#T1){ref-type="table"}). The PPV for complete loss of taste and/or smell (86% \[95% CI, 49%--97%\]) was the highest among any of the symptoms.

DISCUSSION {#s3}
==========

In this household-based population of individuals with COVID-19, including mildly symptomatic individuals who otherwise may not have been tested according to contemporaneous public health guidance \[[@CIT0008]\], loss of taste and/or smell was reported by \>3 of every 5 individuals with confirmed COVID-19. Among the 64 household contacts of COVID-19 index cases, it had the highest PPV of all symptoms, matched only by shortness of breath. When compared to other symptoms, loss of taste and/or smell appeared highly predictive of SARS-CoV-2 infection and was more predictive than cough.

Nasal congestion alone is unlikely to explain the taste and smell alterations, as one-third of patients reporting loss of taste and/or smell did not report nasal congestion; other analyses have shown an even smaller proportion of COVID-19 cases with concurrent nasal congestion \[[@CIT0009]\]. Investigations into the mechanism of COVID-19--related olfactory and taste dysfunction include demonstration of olfactory nerve infection by SARS-CoV, the virus that causes SARS, and expression of angiotensin-converting enzyme 2 (ACE2), the receptor involved in SARS-CoV-2 pathogenesis, on olfactory epithelial cells in animal models \[[@CIT0005], [@CIT0010]\]. Studies in human models have shown broad expression of ACE2 on the epithelial cells of the tongue and oral cavity mucosa \[[@CIT0011], [@CIT0012]\]. The underlying mechanism for these symptoms is an area of active investigation.

This analysis is subject to limitations. All symptoms and medical histories were self-reported and limited by patient recall, health literacy, and availability of home thermometers. Because, prior and current symptom ascertainment and SARS-CoV-2 testing were conducted at enrollment, any subsequent development of symptoms or infection that could affect PPVs was not captured, and timelines for preenrollment symptoms are not available. However, this approach likely reduced selection biases that may be present in other reports describing the association between loss of taste and smell with SARS-CoV-2 infection. Due to the high prevalence (25%) of COVID-19 infection within this population, the PPVs identified in this analysis may not be representative of all clinical encounters. However, our findings may be particularly relevant for screening individuals in close contact with known cases. Finally, the sample size was small, resulting in wide overlapping CIs for the reported PPVs.

In this investigation, adding loss of taste and/or smell to the classic clinical criteria would have captured 95% of cases while only misidentifying 2 noncases as cases, compared to 14 noncases that would have been misidentified by the classic symptoms. In the absence of confirmatory laboratory testing, CSTE criteria for a probable COVID-19 case now include loss of taste and/or smell in conjunction with other nonclassic symptoms \[[@CIT0003]\]. Our findings suggest that adding loss of taste and/or smell to the singular CSTE clinical criteria, which currently include cough, shortness of breath, and difficulty breathing, may increase the efficiency of probable COVID-19 case identification.

Due to limited testing capacity, most states have prioritized testing of moderately to severely ill patients. However, as the availability of contact tracing and testing expands, testing and diagnoses will shift to include outpatients with milder illness. Identifying these cases will assist in appropriate isolation recommendations and the prevention of additional spread within the community. Clinicians will benefit from further characterization of the full spectrum of illness in patients and may consider using loss of taste and/or smell in their testing strategies.
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